E11 Bio - Bryant McGill

# E11 Bio **Entity class:** Nonprofit connectomics research organization **Organizational form:** [[wiki/Focused Research Organization|Focused Research Organization]] **Collections:** [[collections/Neurotech|Neurotech]] · [[collections/Consciousness Continuity|Consciousness Continuity]] **Canonical source articles:** [[articles/The Organic-Synthetic Brain Atlas|The Organic-Synthetic Brain Atlas]] · [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]] ## Definition **E11 Bio** is a nonprofit Focused Research Organization developing technologies for scalable mammalian connectomics. Its central public platform is [[wiki/PRISM (E11 Bio)|PRISM]], an optical and molecular reconstruction architecture designed to reduce segmentation error, improve robustness across sample defects, and add molecular context to reconstructed neurons. E11 describes itself as philanthropically funded and as a Convergent Research FRO. Its current team integrates protein engineering, tissue chemistry, microscopy, neuroanatomy, machine learning, volumetric computing, scientific operations, and open-tool distribution. ## Institutional chronology The source record contains two different milestone dates. [[wiki/Convergent Research|Convergent Research]] says E11 was **established in 2021** in Alameda, California. E11's own FRO page says it was **launched in 2022**. These statements may refer to different stages of formation, incubation, and public operation, but the sources do not settle that interpretation; both are retained with their original verbs. E11 publicly announced its PRISM roadmap on December 3, 2024 and released the preprint and fuller toolbox on October 1, 2025. The 2025 pilot was produced with collaborators connected to [[wiki/Francis Crick Institute|the Francis Crick Institute]], [[wiki/MIT|MIT]], [[wiki/Howard Hughes Medical Institute|HHMI]], [[wiki/Max Planck Institute for Biological Intelligence|the Max Planck Institute for Biological Intelligence]], and [[wiki/MRC Laboratory of Molecular Biology|the MRC Laboratory of Molecular Biology]]. ## Platform and public goods PRISM joins [[wiki/Protein Barcoding|protein barcoding]], [[wiki/Expansion Microscopy|expansion microscopy]], an iterative [[wiki/MAGNIFY|MAGNIFY]] protocol, repeated molecular staining, image registration, machine-learning reconstruction, barcode-augmented automatic proofreading, molecular annotation, large-volume processing through [[wiki/Volara|Volara]], and interactive inspection through [[wiki/Neuroglancer|Neuroglancer]]. E11 distributes PRISM plasmids through [[wiki/Addgene|Addgene]], publishes software and training resources, and releases images, segmentations, predictions, annotations, and training data through [[wiki/E11 Bio PRISM Open Data|E11 Bio PRISM Open Data]]. The associated patent family is represented by [[wiki/WO2025106572A1|WO2025106572A1]]. Patent/legal-entity naming and E11's public nonprofit status remain separate evidence fields. ## People E11's co-founders include [[wiki/Andrew C. Payne|Andrew C. Payne]], [[wiki/Jun Axup Penman|Jun Axup Penman]], [[wiki/Johan Winnubst|Johan Winnubst]], and [[wiki/Kathleen G. C. Leeper|Kathleen G. C. Leeper]]. The PRISM architecture also depends centrally on co-first authors [[wiki/Sung Yun Park|Sung Yun Park]] and [[wiki/Arlo Sheridan|Arlo Sheridan]], computational contributor [[wiki/William Patton|William Patton]], microscopy contributor [[wiki/Sven Truckenbrodt|Sven Truckenbrodt]], and the wider author team. Scientific advisers and collaborating investigators include [[wiki/George Church|George Church]], [[wiki/Ed Boyden|Ed Boyden]], [[wiki/Jan Funke|Jan Funke]], [[wiki/Joergen Kornfeld|Joergen Kornfeld]], and [[wiki/Sam Rodriques|Sam Rodriques]], with role boundaries preserved in the publication's formal contribution statement. ## Roadmap boundary E11's stated path runs from larger mammalian connectomics volumes toward whole-brain mapping and downstream applications in neuroscience, therapeutics, brain-computer interfaces, NeuroAI, and simulation. Its 100-fold cost-reduction path and whole-brain targets are developer projections. The demonstrated record remains the approximately 10-million-µm³ mouse hippocampal PRISM pilot, not a whole mouse brain, human connectome, memory readout, or consciousness transfer. ## Relationships - **Develops:** [[wiki/PRISM (E11 Bio)|PRISM (E11 Bio)]]. - **Organizational form and support:** [[wiki/Focused Research Organization|Focused Research Organization]] and [[wiki/Convergent Research|Convergent Research]]. - **Founders and technical leads:** [[wiki/Andrew C. Payne|Andrew C. Payne]], [[wiki/Jun Axup Penman|Jun Axup Penman]], [[wiki/Johan Winnubst|Johan Winnubst]], and [[wiki/Kathleen G. C. Leeper|Kathleen G. C. Leeper]]. - **Open infrastructure:** [[wiki/Addgene|Addgene]], [[wiki/Volara|Volara]], [[wiki/E11 Bio PRISM Open Data|E11 Bio PRISM Open Data]], and [[wiki/Neuroglancer|Neuroglancer]]. - **Intellectual property:** [[wiki/WO2025106572A1|WO2025106572A1]]. - **Continuity boundary:** relevant to acquisition and reconstruction; does not establish mind uploading or state sufficiency. - **Collection route:** [[collections/Neurotech|Neurotech]]. ## Sources - [E11 Bio — home and mission](https://www.e11.bio/) - [E11 Bio — Focused Research Organization](https://www.e11.bio/fro) - [E11 Bio — team](https://www.e11.bio/team) - [E11 Bio — PRISM release](https://www.e11.bio/blog/prism) - [E11 Bio — roadmap](https://www.e11.bio/blog/roadmap) - [Convergent Research — E11 Bio](https://www.convergentresearch.org/ecosystem/e11-bio) - [PubMed Central — PRISM preprint](https://pmc.ncbi.nlm.nih.gov/articles/PMC12485930/) ## Research Inferences  These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. The interpretive frame comes from [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]] and [[articles/Mind Uploading and AI — The Host is Reusable and the Person is the Delta|Mind Uploading and AI — The Host is Reusable and the Person is the Delta]]. Collection route: [[collections/Neurotech|Neurotech]]. - **INF-0101 — Developer projection with demonstrated subsystem.** PRISM combines protein barcoding, expansion microscopy, iterative molecular staining, and learned reconstruction as an optical alternative to parts of the electron-microscopy path. E11 projects an aggregate 100× cost reduction; the demonstrated record is the 2025 mouse-hippocampal pilot, not whole-brain cost validation.  ## Research Inference Attractors  These are secondary semantic placements for the inference attractor network. Each statement keeps its original ID and tier; its canonical cluster page links back to every destination. Source register: [[research/Research Inferences|Research Inferences]]. Interpretive context: [[articles/Technologies for Consciousness Mapping and Transfer|Technologies for Consciousness Mapping and Transfer]] and [[articles/Mind Uploading and AI — The Host is Reusable and the Person is the Delta|Mind Uploading and AI — The Host is Reusable and the Person is the Delta]]. Collection route: [[collections/Neurotech|Neurotech]]. - **INF-0453 — Established.** Research nonprofits producing for-profit spin-outs with overlapping founders is a repeated and documented pattern in this sector. The structure moves publicly or philanthropically funded capability into private hands lawfully and quickly, and it recurs because it works. - **Canonical cluster:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] - **INF-0458 — Strongly indicated.** Capability travels with people, so tracking where specific researchers work locates capability more reliably than tracking patents or publications. Personnel movement is public, dated, and rarely analyzed systematically. - **Canonical cluster:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] - **INF-0460 — Strongly indicated.** Control of foundational patents in delivery, electrodes, or editing determines who may commercialize regardless of who invented what. Patent landscape analysis predicts market structure years ahead of product announcements. - **Canonical cluster:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] - **INF-0471 — Plausible.** Prizes with precise technical criteria force a field to define what would count as success, which is often the more valuable output. A well-specified prize for residual sufficiency or preservation quality would do more for the field than additional funding. - **Canonical cluster:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] - **INF-0472 — Analytic.** Open publication and open tooling accelerate diffusion but reduce appropriability, which is why capabilities near commercialization close. Watching when a subfield stops publishing is a reliable indicator that it has become valuable. - **Canonical cluster:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] - **INF-0474 — Strongly indicated.** Solicitations, awards, and contract line items are public and specify capability requirements in technical detail. Procurement documents are the highest-quality public source on state intent and are consistently underused. - **Canonical cluster:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]]